Starpharma Holdings
Starpharma Holdings Limited, headquartered in Australia, is a pioneering biotechnology company renowned for its innovative work in drug delivery and development. Founded in 1996, Starpharma has made significant strides in the pharmaceutical industry, particularly in the areas of dendrimer-based therapies and antiviral products. The company’s flagship product, VivaGel®, is a unique antiviral and antibacterial gel that has garnered attention for its efficacy in preventing sexually transmitted infections. Starpharma's commitment to research and development has positioned it as a leader in the biotech sector, with a strong focus on enhancing the safety and effectiveness of existing therapies. With a robust pipeline and strategic partnerships, Starpharma continues to expand its market presence, contributing to advancements in healthcare and improving patient outcomes globally.
DitchCarbon Score
How does Starpharma Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Starpharma Holdings's score of 32 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Starpharma Holdings's reported carbon emissions
In 2024, Starpharma Holdings, headquartered in Australia, reported total carbon emissions of approximately 372,220 kg CO2e, comprising 15,040 kg CO2e from Scope 1 and 357,180 kg CO2e from Scope 2. This reflects a decrease from 2023, where emissions were about 401,700 kg CO2e, with Scope 1 emissions at 17,200 kg CO2e and Scope 2 at 384,500 kg CO2e. The trend continues from 2022, which saw total emissions of around 442,350 kg CO2e, with Scope 1 at 25,670 kg CO2e and Scope 2 at 416,680 kg CO2e. Starpharma has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The company has not disclosed any Scope 3 emissions data, indicating a focus primarily on direct and indirect emissions from its operations. The absence of reduction targets suggests that while Starpharma is actively monitoring its emissions, it may not yet have formalised a comprehensive strategy for significant reductions in the near future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 24,400 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 457,400 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Starpharma Holdings is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
